Completed PHASE3 INTERVENTIONAL 2-arm NCT00373607

Efficacy and Safety of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in Peru

Phase 3a: Efficacy, Safety, and Tolerability of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Peruvian Amazon Region

Sponsor: Institute of Tropical Medicine, Belgium

Conditions Malaria

Interventions Dihydroartemisin-piperaquine Mefloquine + Artesunate

Updated 5 times since 2017 Last updated: Sep 13, 2010 Started: Jul 31, 2003 Primary completion: Jul 31, 2005 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00373607, this PHASE3 trial focuses on Malaria and remains completed. Sponsored by Institute of Tropical Medicine, Belgium, it has been updated 5 times since 2003, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institute of Tropical Medicine, Belgium

Data source: Institute of Tropical Medicine, Belgium

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.